Biocon Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 0.5 per equity share.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's Board approved audited FY2026 financial results and recommended a final dividend of Rs. 0.50 per share (10% on face value of Rs. 5), payable by August 31, 2026 with record date July 3, 2026. Key governance changes include switching statutory auditors from B S R & Co. to S R Batliboi & Associates LLP, and appointing six new directors including five Independent Directors (Rajiv Malik, Daniel Bradbury, Peter Piot, Arun Chandavarkar, Nivruti Rai) and one Non-Executive Director (Thomas Jason Roberts). The Board approved acquiring the remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) via a share-swap preferential issue of ~87.9 lakh Biocon shares at Rs. 376.16 per share, totaling ~Rs. 330.73 crore. BBL will become ~99.99% owned post transaction. Separately, convertible debentures (OCDs and CCDs) held by Goldman Sachs and Edelweiss in BBL were converted into BBL equity shares. A new Long-Term Incentive Plan (Biocon Unity LTIP 2026) was also approved.
Dividend is modest and consistent with prior year. Major strategic move is full integration of BBL, simplifying corporate structure; the share-swap issuance will dilute existing shareholders by ~87.9 lakh shares. Strong board refresh with global pharma veterans signals strategic intent.